Entospletinib,Lanraplenib
Kronos Bio,gilead
[]
$kron kronos bio continues to advance investigational syk inhibitors entospletinib and lanraplenib with new preclinical data at eha2022 congress 
Free Stock Market News are delayed 15 sec. Full features and live news available here: https://t.co/fWRacb3Vft